Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab

Bibliographic Details
Main Author:	Liyi Zhang
Format:	Article
Language:	English
Published:	Elsevier 2021-01-01
Series:	Asia-Pacific Journal of Oncology Nursing
Online Access:	http://www.apjon.org/article.asp?issn=2347-5625;year=2021;volume=8;issue=4;spage=349;epage=351;aulast=Zhang

Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China
by: Zhiyuan Tang, et al.
Published: (2022-09-01)

Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer
by: Yunxiang Zhou, et al.
Published: (2023-08-01)

A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer
by: Moudi M. Alasmari
Published: (2022-12-01)

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial
by: Naveen Reddy, et al.
Published: (2024-03-01)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2022-12-01)

Erratum: Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial
Published: (2024-03-01)

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
by: Joseph Gligorov, et al.
Published: (2022-08-01)

Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab
by: Ma P, et al.
Published: (2015-03-01)

Emerging role of biosimilars: Focus on trastuzumab and metastatic human epidermal growth factor receptor 2-positive breast cancer
by: Lyudmila U. Sarder, et al.
Published: (2023-12-01)

Quantifying the Effects of Combination Trastuzumab and Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
by: Meghan J. Bloom, et al.
Published: (2022-08-01)

Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer
by: Sachin S Hingmire, et al.
Published: (2017-01-01)

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study
by: Yukinori Ozaki, et al.
Published: (2022-01-01)

Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer
by: Jiangping Yang, et al.
Published: (2023-05-01)

Risk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer
by: Wesam Abdel-Razaq, et al.
Published: (2019-01-01)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
by: Edith A. Perez, et al.
Published: (2019-05-01)

Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review
by: Guiramand Jérôme, et al.
Published: (2011-10-01)

Short-course adjuvant trastuzumab will increase cure rates in patients with human epidermal growth factor receptor 2-positive breast cancer
by: Raymond Pierre Abratt
Published: (2017-08-01)

The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies
by: Sara A. Hurvitz, et al.
Published: (2012-09-01)

Human epidermal growth factor receptor-2 expression in head and neck squamous cell carcinoma: A potential for targeted therapy?
by: Ravi C Nayar, et al.
Published: (2016-01-01)

Morphological and clinical characteristics of the head epidermal skin carcinomas
by: Mijović M., et al.
Published: (2015-01-01)

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
by: Edith A. Perez, et al.
Published: (2019-06-01)

Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future
by: Chancellor E. Donald, et al.
Published: (2011-12-01)

The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications
by: Azria David, et al.
Published: (2006-05-01)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022-09-01)

Slip versus Slop: A Head-to-Head Comparison of UV-Protective Clothing to Sunscreen
by: Elizabeth G. Berry, et al.
Published: (2022-01-01)

Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
by: Le-Sang Shen, et al.
Published: (2020-05-01)

Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
by: Zongyu Li, et al.
Published: (2023-06-01)

Metastatic dermatosis in breast carcinoma on adjuvant trastuzumab: Is skin a sanctuary site in human epidermal growth factor receptor-2-amplified disease?
by: Amit Sehrawat, et al.
Published: (2018-01-01)

Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models
by: Magnus Bernhardsson, et al.
Published: (2018-11-01)

Real-world data of cardiotoxicity during long-term therapy with trastuzumab in human epidermal growth factor receptor-2-positive metastatic breast cancer
by: Iljovska Marina, et al.
Published: (2023-01-01)

"Head versus heart"
by: Paul Rozin, et al.
Published: (2007-08-01)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
by: Hye Ryeon Kim, et al.
Published: (2021-12-01)

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer
by: Emma Franco-Mateos, et al.
Published: (2024-04-01)

Abstract: The Submental Versus Groin Vascularized Lymph Node Transfer Flaps: A Head-to-Head Comparison of Surgical Outcomes for Breast Cancer Related Lymphedema
by: Ming-Huei Cheng, MD, MBA, FACS, et al.
Published: (2018-09-01)

313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms
by: Xiaoyu Zhang, et al.
Published: (2020-11-01)

Significance of human epidermal growth factor receptor 2 neu immunostain in head and neck squamous cell carcinoma
by: Ponkhi Doley, et al.
Published: (2020-01-01)

Efficacy of breast shielding during head computed tomography examination
by: Zalokar Nika, et al.
Published: (2020-08-01)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
by: Francesca Ligorio, et al.
Published: (2021-04-01)

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
by: Kazuhiro Araki, et al.
Published: (2018-10-01)

In Silico Study: Combination of α-Mangostin and Chitosan Conjugated with Trastuzumab against Human Epidermal Growth Factor Receptor 2
by: Sandra Megantara, et al.
Published: (2022-07-01)

Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab

Similar Items

Similar Items